Last reviewed · How we verify
Cefadroxil discontinued early
Cefadroxil is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefadroxil is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial skin and soft tissue infections, Urinary tract infections, Respiratory tract infections.
At a glance
| Generic name | Cefadroxil discontinued early |
|---|---|
| Also known as | Clindamycin, Cleocin, Duricef, Ancef, Cefazolin |
| Sponsor | Stony Brook University |
| Drug class | First-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefadroxil works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It is bactericidal and has broad-spectrum activity against gram-positive and some gram-negative bacteria. The drug is typically used for oral treatment of various bacterial infections.
Approved indications
- Bacterial skin and soft tissue infections
- Urinary tract infections
- Respiratory tract infections
- Streptococcal pharyngitis
Common side effects
- Diarrhea
- Nausea
- Hypersensitivity reactions
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefadroxil discontinued early CI brief — competitive landscape report
- Cefadroxil discontinued early updates RSS · CI watch RSS
- Stony Brook University portfolio CI